Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease _ Virology_Antiviral, Antivirus
NanoViricides, Inc. (NYSE MKT:NNVC)

Organization & Developments: NanoVaricides

Parents

2013: OneMedPlace – Sentinel NanoViricides’ drug FluCide found safe in small animal studies (2013)
2014: The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fe
Has full license to TheraCour technologies for developing nanotechnology-based targeted anti-viral therapeutics
NanoViricides
NanoViricides Products are based on TheraCour technology
Pre-clinical biotech with 5 lead candidate anti-viral drugs completing animal studies in preparation for FDA filings.
These drug candidates were designed to destroy HIV, influenza (all strains of influenza A), dengue fever, ocular and topical herpes and ocular adenovirus.